Skip to main content

ANVISA vs. TGA · FDA · CE MDR · Health Canada · HSA

This page provides a high-level comparison of ANVISA's medical device regulatory framework with other major regulators.

Framework comparison

FeatureANVISA (Brazil)FDA (US)EU (MDR)TGA (Australia)Health CanadaHSA (Singapore)
Risk classesI, II, III, IVI, II, IIII, IIa, IIb, IIIClass I–III (ARTG)Class I–IVClass A–D
Pre-market reviewNotificação/Cadastro/Registro510(k)/De Novo/PMACE certificationTGA conformity assessmentLicence applicationHSA application
Registration holderImporter (typically)Manufacturer (direct)Manufacturer (via EU rep)SponsorManufacturer/importerImporter/manufacturer
GMP requirementCBPF (RDC 752/2022)QMSR (21 CFR Part 820)ISO 13485 / MDSAPISO 13485 / TGA auditISO 13485 / MDSAPISO 13485
Registration validity10 yearsIndefinite (subject to changes)Certificate: 5 yearsARTG: indefiniteLicence: variesRegistration: varies
Language requirementPortuguese (Brazil)EnglishEnglish/national languageEnglishEnglish/FrenchEnglish
IMDRF memberYes (full, since 2020)YesYesYesYesYes
MDSAP participationNoYesNo (some CBs)YesYesNo

Leveraging existing regulatory approvals for Brazil

Existing approvalBenefit for Brazil
FDA 510(k) or PMAClinical data, technical documentation largely reusable
CE MDR certificateCER, essential requirements checklist, ISO 13485 — all reusable
TGA registrationStrong basis for ANVISA clinical evidence section
Health Canada licenceUseful supplementary evidence

Always adapt documentation to ANVISA's specific format requirements and translate all submissions into Portuguese.


Official sources

Verify all information against official ANVISA sources before making regulatory decisions.